Corvus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CRVS Corvus Pharmaceuticals Inc
DDAIF Daimler AG
REI Ring Energy Inc
CZSVF Goldcore Resources Ltd
AAPL Apple Inc
PMBC Pacific Mercantile Bancorp
MSFT Microsoft Corp
O Realty Income Corp
CRLBF Cresco Labs Inc
KSDIX Keeley Small Cap Dividend Value Fund Class I
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Closing Price
$3.48
Day's Change
-0.10 (-2.79%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.69
Day's Low
3.31
Volume
(Light)
Volume:
1,746,270

10-day average volume:
2,877,587
1,746,270

Upcoming Events

CRVS's fiscal year ends in December
There are no upcoming events for CRVS

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
October 29, 2020Q3 2020 Earnings Release-$0.33-$0.33 to -$0.18-$0.37
July 30, 2020Q2 2020 Earnings Release-$0.36-$0.43 to -$0.20-$0.44
April 30, 2020Q1 2020 Earnings Release-$0.44-$0.42 to -$0.372-$0.40
March 5, 2020Q4 2019 Earnings Release-$0.38-$0.384 to -$0.29--

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.